Postmarketing Clinical Experience in Patients with Skin and Skin-Structure Infections Treated with Daptomycin
| Autor: | Lawrence V. Friedrich, Robert C. Owens, Kenneth C. Lamp, Rene Russo |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Population Antibiotics Skin infection medicine.disease_cause Daptomycin Internal medicine Product Surveillance Postmarketing medicine Humans education Gram-Positive Bacterial Infections Aged Antibacterial agent education.field_of_study business.industry Soft Tissue Infections Skin Diseases Bacterial General Medicine Middle Aged medicine.disease Methicillin-resistant Staphylococcus aureus Anti-Bacterial Agents Surgery Staphylococcus aureus Concomitant Female business medicine.drug |
| Zdroj: | The American Journal of Medicine. 120:S6-S12 |
| ISSN: | 0002-9343 |
| DOI: | 10.1016/j.amjmed.2007.07.009 |
| Popis: | A registry describing daptomycin's clinical use was analyzed to describe treatment of skin and skin-structure infections (SSSIs). The Cubicin Outcomes Registry and Experience (CORE) 2004 retrospectively collected demographic, microbiologic, and clinical outcome information of patients treated with daptomycin (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA). The database was accessed to identify patients with a diagnosis of an SSSI with an outcome determined. Of 577 patients identified with a SSSI, 522 (90%) were evaluable. Diabetes mellitus and peripheral vascular disease were present in 27% and 10% of the population, respectively. Pathogens were identified for 65% of all patients-Staphylococcus aureus (75%; 85% methicillin-resistant) and Enterococcus species (19%; 44% vancomycin-resistant) most commonly. Concomitant use of other antibiotics was common (42%). Of 522 patients studied, 334 (64%) had complicated infections (cSSSIs), and 188 (36%) had uncomplicated infections (uSSSIs). Overall cure, improved, and failure rates were 53%, 43%, and 4%, respectively, for cSSSI and 66%, 32%, and 2%, respectively, for uSSSI. The median dose administered was 4.0 mg/kg for cSSSI (mean, 4.5+/-1.0 mg/kg; range, 2.3 to 12 mg/kg) and 4.0 mg/kg for uSSSI (mean, 4.2+/-0.8 mg/kg; range, 2.1 to 9 mg/kg); the dose was significantly higher in cSSSI (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|